Baricitinib, sold under the brand name Olumiant among others, is an immunomodulatory medication used for the treatment of rheumatoid arthritis, alopecia...

(tafasitamab-cxix) , Opzelura (Ruxolitinib), Tabrecta (capmatinib), Olumiant (Baricitinib), and Iclusig (ponatinib). In 2013, Novartis acquired Incyte's c-Met...

FDA issued an emergency use authorization (EUA) for the combination of baricitinib with remdesivir, for the treatment of suspected or laboratory confirmed...

relative effectiveness of deuruxolitinib and another Janus kinase inhibitor—baricitinib—for alopecia areata may vary depending on the population studied, both...

In June 2022, the U.S. Food and Drug Administration (FDA) authorized baricitinib, a Janus kinase (JAK) inhibitor, for the treatment of severe alopecia...

Administration (FDA) requires a boxed warning for the JAK inhibitors tofacitinib, baricitinib, and upadacitinib to warn about the risks of serious heart-related events...

crizotinib, daclatasvir, sofosbuvir, afatinib, axitinib, brigatinib, baricitinib, cabozantinib, dasatinib, neratinib, eltrombopag, ibrutinib, lenvatinib...

need systemic medicines such as cyclosporin, methotrexate, dupilumab or baricitinib. Other names of the condition include "infantile eczema", "flexural eczema"...

alopecia spironolactone and flutamide. In June 2022, the FDA authorized baricitinib for the treatment of severe alopecia areata. Minoxidil, applied topically...

Later that month, the WHO recommended the rheumatoid arthritis drug Baricitinib for severe or critical patients. It also recommended the monoclonal antibody...